Professional Experience

Steven C. Kline has extensive experience in all aspects of complex patent litigation in the pharmaceutical and chemical arts. Mr. Kline has represented leaders in these technology fields, including AstraZenca, Bausch & Lomb, Bristol-Myers Squibb, Eli Lily, Emory University, Merck, Pfizer, UCB, and Union Carbide. Specific technologies that Mr. Kline has worked with include contact lens cleaning and disinfecting solutions, antipsychotic drugs, antiviral drugs (including AIDS and hepatitis B), anticancer drugs, glaucoma drugs, eye vitamins, medical implant devices, fluidized bed reactor polymerization processes, and carpet dyes. Mr. Kline also has particular experience in litigating ANDA cases brought under the Hatch-Waxman Act. 

His patent litigations include representing: 

• Astra Zeneca against Teva and Sandoz on a patent covering Astra Zeneca’s Seroquel®, an antipsychotic medicine UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to Keppra®, a leading epilepsy medicine.
  
  
• Eli Lilly against Teva Pharmaceuticals on patents involving Lilly's highly successful product Sarafem, which is used to treat Prementrual Dysphoric Disorder (PMDD), a severe form of PMS against Glaxo Wellcome on patents relating to anti-hepatitis pharmaceuticals, and against Glaxo Wellcome and Bio Chem Pharma on patents relating to anti-AIDS pharmaceuticals. 
  
  
• Pfizer against Barr on patents relating to oral contraceptive pharmaceuticals, and against Barr on patents relating to hormone replacement therapy pharmaceuticals. 
  


• Bristol-Myers Squibb against Housey Pharmaceuticals on patents relating to cell based assays and against Rhone-Poulenc Rorer, Inc. et. al. on patents relating to semi-synthetic process technology for making Taxol. 
  


• Bausch & Lomb against Alcon and Allergan on patents relating to compositions for disinfecting contact lenses and against GNC, Leiner, Alcon, and Rexall on a patent relating to a nutritional supplement to prevent macular degeneration.

Education

J.D., cum laude, Tulane University, 1989, Articles Editor, Tulane Maritime Law Journal
B.S. Chemistry, Tulane University, 1986

Bar Admissions

State of New York, 1990; U.S. Court of Appeals for the Federal Circuit; U.S. District Courts for the Southern, Eastern and Western Districts of New York

Professional Activities

American Intellectual Property Law Association; New York Intellectual Property Law Association

Related Information

Representative Cases

AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd., v. Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd and Sandoz, Inc.
Fed. Cir. 2009

Unigene Labs., Inc., et al. v. Apotex, Inc., et al.
S.D.N.Y., 2009

AstraZeneca Pharmaceutical LP et al. v. Teva Pharmaceuticals USA, Inc, et al.
D.N.J. 2008

AstraZeneca Pharmaceuticals LP, et al. v. Teva Pharmaceuticals USA, Inc., et al.
D.N.J. 2007

UCB Societe Anonyme & UCB Pharma Inc. v. Mylan Laboratories, Inc. et al
N.D. GA 2006

Eli Lilly and Company, et al. v. Teva Pharmaceuticals USA, Inc.
Fed. Cir. 2005

Eli Lilly and Company, et al. v. Teva Pharmaceuticals USA, Inc.
S.D. Indiana 2004

Housey Pharmaceuticals v. Bristol-Myers Squibb Co.
Fed. Cir. 2004

Bristol-Myers Squibb Company v. Rhone-Poulenc Rorer, Inc. et. al.
Fed. Cir. 2003

Housey Pharmaceuticals v. Bristol-Myers Squibb Co.
D.Del 2002

Bausch & Lomb, Inc. v. Alcon Laboratories, Inc.
W.D.N.Y. 1999



Events

Five Ways to Reduce the Risk and Cost of Complex Intellectual Property Litigation and eDiscovery
Inside Counsel
March 3, 2010



Press Releases

Fitzpatrick Commences Legal Action on Behalf of Client AstraZeneca Over Seroquel Patent
November 14, 2005